Cargando…

Diabetes induced by checkpoint inhibition in nonobese diabetic mice can be prevented or reversed by a JAK1/JAK2 inhibitor

OBJECTIVES: Immune checkpoint inhibitors have achieved clinical success in cancer treatment, but this treatment causes immune‐related adverse events, including type 1 diabetes (T1D). Our aim was to test whether a JAK1/JAK2 inhibitor, effective at treating spontaneous autoimmune diabetes in nonobese...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ge, Tingting, Phung, Amber‐Lee, Jhala, Gaurang, Trivedi, Prerak, Principe, Nicola, De George, David J, Pappas, Evan G, Litwak, Sara, Sanz‐Villanueva, Laura, Catterall, Tara, Fynch, Stacey, Boon, Louis, Kay, Thomas W, Chee, Jonathan, Krishnamurthy, Balasubramanian, Thomas, Helen E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618467/ https://www.ncbi.nlm.nih.gov/pubmed/36325490 http://dx.doi.org/10.1002/cti2.1425

Ejemplares similares

The JAK1 Selective Inhibitor ABT 317 Blocks Signaling Through Interferon-γ and Common γ Chain Cytokine Receptors to Reverse Autoimmune Diabetes in NOD Mice
por: Ge, Tingting, et al.
Publicado: (2020)

IL-21 regulates SOCS1 expression in autoreactive CD8(+) T cells but is not required for acquisition of CTL activity in the islets of non-obese diabetic mice
por: Sutherland, Andrew P. R., et al.
Publicado: (2019)

Complete Diabetes Protection Despite Delayed Thymic Tolerance in NOD8.3 TCR Transgenic Mice Due to Antigen-Induced Extrathymic Deletion of T Cells
por: Krishnamurthy, Balasubramanian, et al.
Publicado: (2012)

Soluble FAS ligand is not required for pancreatic islet inflammation or beta-cell destruction in non-obese diabetic mice
por: Trivedi, Prerak M., et al.
Publicado: (2019)

Tolerance to Proinsulin-1 Reduces Autoimmune Diabetes in NOD Mice
por: Jhala, Gaurang, et al.
Publicado: (2021)

NF-κB is weakly activated in the NOD mouse model of type 1 diabetes
por: Irvin, Allison E., et al.
Publicado: (2018)

Granzyme B Is Dispensable in the Development of Diabetes in Non-Obese Diabetic Mice
por: Mollah, Zia U., et al.
Publicado: (2012)

JAK/STAT signaling in diabetic kidney disease
por: Liu, Yingjun, et al.
Publicado: (2023)

JAK/STAT signaling in hepatocellular carcinoma
por: Hin Tang, Justin Jit, et al.
Publicado: (2020)

ROCKing the JAKs
por: Peelman, Frank, et al.
Publicado: (2013)

The Jak Tree
Publicado: (1889)

Androgen treatment prevents diabetes in nonobese diabetic mice
Publicado: (1992)

An overview of JAK/STAT pathways and JAK inhibition in alopecia areata
por: Lensing, Maddison, et al.
Publicado: (2022)

Relationship between postprandial endotoxemia in nonobese postmenopausal women and diabetic nonobese postmenopausal women
por: Zaman, Gaffar Sarwar, et al.
Publicado: (2015)

Requirement of Fas for the Development of Autoimmune Diabetes in Nonobese Diabetic Mice
por: Itoh, Naoto, et al.
Publicado: (1997)

Spontaneous Autoimmune Diabetes in Monoclonal T Cell Nonobese Diabetic Mice
por: Verdaguer, Joan, et al.
Publicado: (1997)

I-E+ nonobese diabetic mice develop insulitis and diabetes
Publicado: (1993)

Genetic control of diabetes and insulitis in the nonobese diabetic (NOD) mouse
Publicado: (1987)

Breaking self-tolerance in nonobese diabetic mice
Publicado: (1996)

JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial
por: Tuttle, Katherine R, et al.
Publicado: (2018)

IL-17F induces inflammation, dysfunction and cell death in mouse islets
por: Catterall, Tara, et al.
Publicado: (2020)

The Janus kinases (Jaks)
por: Yamaoka, Kunihiro, et al.
Publicado: (2004)

JAKs and STATs in chemoresistance
por: Costa-Pereira, Ana P
Publicado: (2010)

JAK-STAT and feeding
por: Ladyman, Sharon R., et al.
Publicado: (2013)

Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application
por: Furqan, Muhammad, et al.
Publicado: (2013)

A review of JAK–STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition
por: McInnes, Iain B, et al.
Publicado: (2021)

Atomic Simulation of the Binding of JAK1 and JAK2 with the Selective Inhibitor Ruxolitinib
por: Kondratyev, Maxim, et al.
Publicado: (2022)

Drosophila Jak/STAT Signaling: Regulation and Relevance in Human Cancer and Metastasis
por: Trivedi, Sunny, et al.
Publicado: (2018)

The Role of Macrophages in T Cell–mediated Autoimmune Diabetes in Nonobese Diabetic Mice
por: Jun, Hee-Sook, et al.
Publicado: (1999)

Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis
por: Tvorogov, Denis, et al.
Publicado: (2018)

Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies
por: Passamonti, Francesco, et al.
Publicado: (2011)

Heterodimeric JAK-STAT Activation as a Mechanism of Persistence to JAK2 Inhibitor Therapy
por: Koppikar, Priya, et al.
Publicado: (2012)

Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
por: Pardanani, A, et al.
Publicado: (2013)

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis
por: Boyle, D L, et al.
Publicado: (2015)

Receptor-mediated dimerization of JAK2 FERM domains is required for JAK2 activation
por: Ferrao, Ryan D, et al.
Publicado: (2018)

Nonobese, Nonketotic Childhood-Onset Diabetes: Look for Lipodystrophies
por: Chakraborty, Partha P., et al.
Publicado: (2017)

Metabolomic Profiles of Nonobese and Obese Women With Gestational Diabetes
por: Sormunen-Harju, Heidi, et al.
Publicado: (2023)

JAK/STAT Pathway Mutations in T-ALL, Including the STAT5B N642H Mutation, are Sensitive to JAK1/JAK3 Inhibitors
por: Govaerts, Inge, et al.
Publicado: (2019)

A JAK/STAT invasion
por: Wells, William A.
Publicado: (2002)

Zobacz, jak powstał wszechświat
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_4q0fbouiad6rdq8ui1bkk04ab7